In silico analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells

Table 3 Summary of lncRNA-miRNA-mRNA interactions in HepG2 and SNU449 cells at 24 hours of Sorafenib treatment

lncRNA	miRNA	mRNA	Condition
MIR4435-2HG	hsa-miR-3187-3p	ATOH8	HepG2 24 hours
MALAT1	hsa-miR-769-5p	FAXDC2
ZFAS1	hsa-miR-193b-3p	SIAH1
THAP9-AS1	hsa-miR-374b-3p	SMAD7
MALAT1	hsa-miR-374b-3p
MALAT1	hsa-miR-769-5p	TFAP4
SNHG17	hsa-miR-769-5p
MALAT1	hsa-miR-374b-3p	TIPARP
SNHG12	hsa-let-7b-5p	ADRB2	SNU449 24 hours
EPB41 L4A-AS1	hsa-miR-195-5p
PVT1	hsa-miR-195-5p
LINC01578	hsa-miR-195-5p
GAS5	hsa-miR-374c-5p	CEBPB
SNHG5	hsa-miR-374c-5p
SNHG7	hsa-miR-34a-5p	KLF4
EPB41 L4A-AS1	hsa-miR-195-5p	VEGFA
PVT1	hsa-miR-195-5p
LINC01578	hsa-miR-195-5p
GAS5	hsa-miR-374c-5p
SNHG5	hsa-miR-374c-5p